AR and prostate cancer: Here, we demonstrate for the first time that our proprietary novel retinamides can simultaneously inhibit both AR signaling and MNK facilitated eIF4E translation initiation and impede growth and progression of in androgen dependent (LNCaP) and castration resistant (C4-2B, 22Rv1) prostate cancer cells.